The alliance will leverage Mission Bio’s Tapestri Platform to investigate Onconova’s novel cancer therapy rigosertib, through clinical trials NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics , Inc. (NASDAQ: ONTX) , a Phase 3 stage
Conference Call and Webcast at 9 a.m. Eastern Time on August 14, 2019 NEWTOWN, Pa., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on
NEWTOWN, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced two presentations at
NEWTOWN, Pa., May 28, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it will be
NEWTOWN, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS), today provided
Onconova to Receive $4 Million Upfront, including $2 Million Fee and $2 Million for Onconova Shares Purchased at a Premium, Plus up to $45.5 Million in Regulatory and Sales Milestones for Rigosertib in Greater China HanX to Dedicate $2 Million in Local Currency to Invest in Greater China Rigosertib
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, May 14, 2019 NEWTOWN, Pa., May 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug
NEWTOWN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced
NEWTOWN, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Company will
NEWTOWN, Pa., March 26, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided
Full enrollment of 360 patients anticipated in second half of 2019 Pivotal global study continues enrolling worldwide Potential for first new therapy in 15 years to address unmet medical need in MDS NEWTOWN, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, March 26, 2019 NEWTOWN, Pa., March 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
NEWTOWN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will
NEWTOWN, Pa., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes
Invitation-only breakfast event sponsored by Onconova Therapeutics will also be webcast, beginning at 8:00 a.m. EST NEWTOWN, Pa., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) , a Phase 3 stage biopharmaceutical company focused on discovering and developing novel
